Journal of Clinical Endocrinology & Metabolism, Vol 75, 1514-1518, Copyright © 1992 by Endocrine Society

ARTICLES

Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets

SA Rivkees, G el-Hajj-Fuleihan, EM Brown and JD Crawford
Pediatric Endocrine Unit, Massachusetts General Hospital, Boston 02114.

We report the development of severe tertiary hyperparathyroidism in three girls treated for familial hypophosphatemic rickets and characterize parathyroid function in vivo and in vitro. All patients had been previously treated with relatively large doses of inorganic phosphorus (125 mm/day) and ergocalciferol or calcitriol for several years and had radiographic evidence of long-standing hyperparathyroidism. Even in the presence of extremely elevated PTH levels, oral phosphate lowered serum calcium levels in vivo and further stimulated PTH secretion. Profound multiglandular parathyroid hyperplasia was found in each patient at surgery. Examination of the secretory characteristics of the excised parathyroid tissue revealed that either relatively high calcium concentrations were generally needed to suppress PTH secretion or PTH secretion was not suppressible. Caution is recommended when relatively large doses of phosphate are used to treat familial hypophosphatemic rickets.

This article has been cited by other articles:

				X. Bai, D. Miao, D. Goltzman, and A. C. Karaplis Early Lethality in Hyp Mice with Targeted Deletion of Pth Gene Endocrinology, October 1, 2007; 148(10): 4974 - 4983. [Abstract] [Full Text] [PDF]

				R. M. Savio, J. E. Gosnell, S. Posen, T. S. Reeve, and L. W. Delbridge Parathyroidectomy for Tertiary Hyperparathyroidism Associated With X-linked Dominant Hypophosphatemic Rickets Arch Surg, February 1, 2004; 139(2): 218 - 222. [Abstract] [Full Text] [PDF]

				K. Sato, T. Obara, K. Yamazaki, M. Kanbe, K. Nakajima, A. Yamada, T. Yanagisawa, Y. Kato, T. Nishikawa, and K. Takano Somatic Mutations of the MEN1 Gene and Microsatellite Instability in a Case of Tertiary Hyperparathyroidism Occurring during High Phosphate Therapy for Acquired, Hypophosphatemic Osteomalacia J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5564 - 5571. [Abstract] [Full Text] [PDF]

				S. J. Yeung, I. E. McCutcheon, P. Schultz, and R. F. Gagel Use of Long-Term Intravenous Phosphate Infusion in the Palliative Treatment of Tumor-Induced Osteomalacia J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 549 - 555. [Abstract] [Full Text]

				I. V. Silva, C. J. Blaisdell, S. E. Guggino, and W. B. Guggino PTH regulates expression of ClC-5 chloride channel in the kidney Am J Physiol Renal Physiol, February 1, 2000; 278(2): F238 - F245. [Abstract] [Full Text] [PDF]

				R. Nehgme, J. T. Fahey, C. Smith, and T. O. Carpenter Cardiovascular Abnormalities in Patients with X-Linked Hypophosphatemia J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2450 - 2454. [Abstract] [Full Text] [PDF]